Skip to content

MDMA: all studies

Page 92 of 347: studies 911 to 920 of 3,461, newest first. Back to the MDMA overview

Research

Making a medicine out of MDMA.

The British Journal of Psychiatry 2015 Ben Sessa, David Nutt 36 citations

From its first use 3,4,-methylenedioxymethamphetamine (MDMA) has been recognised as a drug with therapeutic potential. Research on its clinical utility stopped when it entered the recreational drug scene but has slowly resurrected in the past decade. Currently there is enough evidence for MDMA to be removed from its Schedule 1 status of 'no medical use' and moved into Schedule 2 (alongside...

The variability of ecstasy tablets composition in Brazil.

Journal of Forensic Sciences 2015 Loraine R Togni, Rafael Lanaro, Rodrigo R Resende et al. 54 citations

The content of ecstasy tablets has been changing over the years, and nowadays 3,4-methylenedioxymethamphetamine (MDMA) is not always present in the tablets. The aim of this study was to investigate the chemical composition in the seized tablets labeled as ecstasy. We analyzed samples from 150 different seizures made by Sao Paulo's State Police by gas chromatography-mass spectrometry. MDMA was...

DOI: 10.1111/1556-4029.12584 (opens in new tab) Full text (opens in new tab) MDMA Chemical profiling Designer drugs Forensic science +4

Autophagy activation is involved in 3,4-methylenedioxymethamphetamine ('ecstasy')--induced neurotoxicity in cultured cortical neurons.

PLoS One December 31, 2014 I-Hsun Li, Kuo-Hsing Ma, Shao-Ju Weng et al. 40 citations

Autophagic (type II) cell death, characterized by the massive accumulation of autophagic vacuoles in the cytoplasm of cells, has been suggested to play pathogenetic roles in cerebral ischemia, brain trauma, and neurodegenerative disorders. 3,4-Methylenedioxymethamphetamine (MDMA or ecstasy) is an illicit drug causing long-term neurotoxicity in the brain. Apoptotic (type I) and necrotic (type...

DOI: 10.1371/journal.pone.0116565 (opens in new tab) Full text (opens in new tab) Neurons Cells, cultured Animals Rats, sprague-dawley +7

Effects of methylphenidate and MDMA on appraisal of erotic stimuli and intimate relationships

European Neuropsychopharmacology December 4, 2014 Yasmin Schmid, Cédric M. Hysek, Katrin H. Preller et al. 39 citations

Methylphenidate mainly enhances dopamine neurotransmission whereas 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") mainly enhances serotonin neurotransmission. However, both drugs also induce a weaker increase of cerebral noradrenaline exerting sympathomimetic properties. Dopaminergic psychostimulants are reported to increase sexual drive, while serotonergic drugs typically impair sexual...

Brain serotonin synthesis in MDMA (ecstasy) polydrug users: an alpha-[(11) C]methyl-l-tryptophan study.

Journal of Neurochemistry December 2014 Linda Booij, Jean‐Paul Soucy, Simon N. Young et al.

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) use may have long-term neurotoxic effects. In this study, positron emission tomography with the tracer alpha-[(11) C]methyl-l-tryptophan ((11) C-AMT) was used to compare human brain serotonin (5-HT) synthesis capacity in 17 currently drug-free MDMA polydrug users with that in 18 healthy matched controls. Gender differences and associations...

Memory and mood during MDMA intoxication, with and without memantine pretreatment.

Neuropharmacology December 2014 E B De Sousa Fernandes Perna, E L Theunissen, K P C Kuypers et al.

Previous studies have shown that single doses of MDMA can affect mood and impair memory in humans. The neuropharmacological mechanisms involved in MDMA-induced memory impairment are not clear. Memantine, an NMDA and alpha 7 nicotinic acetylcholine (ACh) receptor antagonist, was able to reverse MDMA-induced memory impairment in rats. This study investigated whether treatment with memantine can...

Current preclinical studies on neuroinflammation and changes in blood-brain barrier integrity by MDMA and methamphetamine.

Neuropharmacology December 2014 Esther O'Shea, Andrés Urrutia, Alfred Richard Green et al.

The blood-brain barrier (BBB) is essential in the maintenance of brain homeostasis both by preserving normal brain functioning and also by protecting the brain from exposure to a range of potentially harmful substances. This review presents some of the evidence of BBB disruption following exposure to the substituted amphetamines 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and...

DOI: 10.1016/j.neuropharm.2014.02.015 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Basal lamina proteins Blood–brain barrier disruption Igg extravasation +1

A study on the mechanism by which MDMA protects against dopaminergic dysfunction after minimal traumatic brain injury (mTBI) in mice.

Journal of Molecular Neuroscience December 1, 2014 Shahaf Edut, Vardit Rubovitch, M Rehavi et al. 18 citations

Driving under methylenedioxymethamphetamine (MDMA) influence increases the risk of being involved in a car accident, which in turn can lead to traumatic brain injury. The behavioral deficits after traumatic brain injury (TBI) are closely connected to dopamine pathway dysregulation. We have previously demonstrated in mice that low MDMA doses prior to mTBI can lead to better performances in...

The Role of Adenosine A1 and A2A Receptors in the Caffeine Effect on MDMA-Induced DA and 5-HT Release in the Mouse Striatum

Neurotoxicity Research November 13, 2014 Anna Górska, Krystyna Gołembiowska 36 citations

3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") popular as a designer drug is often used with caffeine to gain a stronger stimulant effect. MDMA induces 5-HT and DA release by interaction with monoamine transporters. Co-administration of caffeine and MDMA may aggravate MDMA-induced toxic effects on DA and 5-HT terminals. In the present study, we determined whether caffeine influences DA and...